Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Estradiol Levels and Lung Cancer Outcomes
Author
Howard (Jack) West, MD

This work is still early, but it's been interesting to see a lab-based correlate emerge along with with the observation of women, and particularly older women, doing better in lung cancer studies (several prior posts here). Last year, the folks at Cell Therapeutics, Inc., analyzed results from their trials with Xyotax (post here), which demonstrated that their favorable results were seen in younger women. Estrogen may be very relevant to several biological processes related to lung cancer (reviewed in this post), so there is reason to believe that sex differences in lung cancer outcomes are plausible.

Results at ASCO this year were notable for a couple of presentations that noted a correlation of estradiol levels with lung cancer outcomes. Estradiol is the major form of estrogen in humans, the "female" hormone, although levels are present in men as well. The results for women under 60 vs. 60 and older in a couple of xyotax trials were broken down by estradiol levels. Women with lower estradiol levels did better regardless of their age, while those with higher estradiol levels did less well, again regardless of their age:

estradiol and age in women (Click to enlarge)

So age appears to be more of a surrogate for hormonal status than an independent prognostic factor, at least according to an early analysis.

It would be interesting, though, to see if estradiol levels were also prognostic in men, since men also have detectable levels. In fact, that was looked at in the Xyotax trials, and would you believe that the men with lower estradiol levels (below the median) had a significantly longer survival than the men with higher estradiol levels? Here's the figure for the results, among 318 of 583 men on the STELLAR-3 (carbo/taxol vs. carbo/xyotax) or STELLAR-4 trial (gemcitabine or navelbine vs. xyotax) who had serum samples available:

estradiol in men Note: Estradiol levels are measured differently than in the above curve in women, hence the different numbers (scale).

Unlike women on these xyotax trials, men didn't do better with xyotax regardless of their estradiol levels.

There are trials that are just now beginning to look into using anti-estrogen therapies like tamoxifen or faslodex (fulvestrant) in combination with tarceva or other anti-cancer strategies, to see whether they will confer the survival benefit that seems to be present for post-menopausal women to pre-menopausal women, or maybe even men. Right now, we haven't seen the results of these trials, but I'll be watching for more and will keep everyone posted if we learn more.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on